Academic Journal
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.
| العنوان: | Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. |
|---|---|
| المؤلفون: | Bruno S, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, Aghemo A, Cabibbo G, Viganò M, Boccaccio V, Craxí A, Colombo M, Maisonneuve P |
| المساهمون: | Bruno S, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, Aghemo A, Cabibbo G, Viganò M, Boccaccio V, Craxí A, Colombo M, Maisonneuve P |
| سنة النشر: | 2016 |
| المجموعة: | IRIS Università degli Studi di Palermo |
| مصطلحات موضوعية: | HCV |
| الوصف: | Background & Aims: Life expectancy of patients with compensated hepatitis C virus (HCV) cirrhosis achieving sustained virologic response (SVR) is limited by liver events as compared to the general population. Thus, survival benefit of SVR remains to be measured. Methods: The study includes prospective surveillance data from three cohorts of Italian patients with compensated HCV cirrhosis who achieved SVR on an interferon-based (IFN) regimen, compared to simultaneously observed non-SVR, untreated and decompensated patients. Overall survival was calculated from the date of start of IFN to death. The number of deaths expected during the at-risk period was determined by applying age- and sex-specific mortality rates recorded in Italy for person-years adequate for the enrolment period. The standardized mortality ratio (SMR) determined the relative risk of death over that of the age and sex matched general population. Results: Overall, 28/181 patients followed-up for a median period of 9.6 years (range 1–25 years) died. The 10 and 20-year overall survival rates for the whole series were 90.9% (95% CI, 84.3–94.8) and 62.9% (95% CI, 45.9–75.9), respectively. The number of expected deaths in the corresponding age and sex matched general population was 28.1, corresponding to a SMR = 1.00 (95% CI, 0.72–1.35), with an SMR for non-SVR patients of 3.85 (95% CI, 3.43–4.30), for untreated of 3.01 (95% CI, 2.64–3.42) and for decompensated of 6.70 (95% CI, 5.39–8.22). Conclusions: Patients with compensated HCV cirrhosis achieving SVR by IFN obtain a main benefit levelling their survival curve to that of the general population. Wider applicability of IFN-free regimens will possibly make this achievement more generalizable. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/wos/WOS:000375934200007; volume:64; issue:6; firstpage:1217; lastpage:1223; numberofpages:7; journal:JOURNAL OF HEPATOLOGY; http://hdl.handle.net/10447/282341 |
| DOI: | 10.1016/j.jhep.2016.01.034 |
| الاتاحة: | http://hdl.handle.net/10447/282341 https://doi.org/10.1016/j.jhep.2016.01.034 |
| Rights: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.1AC4A340 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.jhep.2016.01.034 |
|---|